vs
Side-by-side financial comparison of John Marshall Bancorp, Inc. (JMSB) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $16.8M, roughly 1.2× John Marshall Bancorp, Inc.). John Marshall Bancorp, Inc. runs the higher net margin — 36.3% vs -20.4%, a 56.7% gap on every dollar of revenue. Over the past eight quarters, John Marshall Bancorp, Inc.'s revenue compounded faster (15.3% CAGR vs 2.9%).
John Marshall Bancorp, Inc. is a U.S.-based bank holding company that operates through its wholly owned subsidiary John Marshall Bank. It provides a full suite of commercial and consumer banking products including deposit accounts, commercial loans, residential mortgages, and personal financial services, primarily serving retail customers and small-to-mid-sized businesses across the U.S. Mid-Atlantic region.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
JMSB vs SGHT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.8M | $20.4M |
| Net Profit | $6.1M | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | — | -18.0% |
| Net Margin | 36.3% | -20.4% |
| Revenue YoY | — | 6.9% |
| Net Profit YoY | 26.8% | 64.9% |
| EPS (diluted) | $0.43 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $16.8M | — | ||
| Q4 25 | $16.4M | $20.4M | ||
| Q3 25 | $16.3M | $19.9M | ||
| Q2 25 | $15.4M | $19.6M | ||
| Q1 25 | $14.6M | $17.5M | ||
| Q4 24 | $14.3M | $19.1M | ||
| Q3 24 | $13.8M | $20.2M | ||
| Q2 24 | $12.6M | $21.4M |
| Q1 26 | $6.1M | — | ||
| Q4 25 | $5.9M | $-4.2M | ||
| Q3 25 | $5.4M | $-8.2M | ||
| Q2 25 | $5.1M | $-11.9M | ||
| Q1 25 | $4.8M | $-14.2M | ||
| Q4 24 | $4.8M | $-11.8M | ||
| Q3 24 | $4.2M | $-11.1M | ||
| Q2 24 | $3.9M | $-12.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% |
| Q1 26 | — | — | ||
| Q4 25 | 47.4% | -18.0% | ||
| Q3 25 | 42.2% | -39.7% | ||
| Q2 25 | 42.7% | -59.6% | ||
| Q1 25 | 42.4% | -79.2% | ||
| Q4 24 | 42.5% | -62.5% | ||
| Q3 24 | 38.8% | -55.7% | ||
| Q2 24 | 39.7% | -59.2% |
| Q1 26 | 36.3% | — | ||
| Q4 25 | 36.2% | -20.4% | ||
| Q3 25 | 33.2% | -41.0% | ||
| Q2 25 | 33.1% | -61.0% | ||
| Q1 25 | 32.9% | -80.8% | ||
| Q4 24 | 33.3% | -62.1% | ||
| Q3 24 | 30.7% | -54.9% | ||
| Q2 24 | 30.9% | -57.7% |
| Q1 26 | $0.43 | — | ||
| Q4 25 | $0.41 | $-0.07 | ||
| Q3 25 | $0.38 | $-0.16 | ||
| Q2 25 | $0.36 | $-0.23 | ||
| Q1 25 | $0.34 | $-0.28 | ||
| Q4 24 | $0.33 | $-0.23 | ||
| Q3 24 | $0.30 | $-0.22 | ||
| Q2 24 | $0.27 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $150.2M | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $268.1M | $63.9M |
| Total Assets | $2.4B | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $150.2M | — | ||
| Q4 25 | $130.0M | $92.0M | ||
| Q3 25 | $163.6M | $92.4M | ||
| Q2 25 | $116.9M | $101.5M | ||
| Q1 25 | $169.1M | $108.8M | ||
| Q4 24 | $122.5M | $120.4M | ||
| Q3 24 | $177.2M | $118.6M | ||
| Q2 24 | $182.6M | $118.2M |
| Q1 26 | — | — | ||
| Q4 25 | $80.9M | $42.4M | ||
| Q3 25 | $80.9M | $42.4M | ||
| Q2 25 | $80.8M | $42.4M | ||
| Q1 25 | $80.8M | $42.4M | ||
| Q4 24 | $80.8M | $40.0M | ||
| Q3 24 | $80.8M | $37.1M | ||
| Q2 24 | $24.7M | $35.0M |
| Q1 26 | $268.1M | — | ||
| Q4 25 | $265.6M | $63.9M | ||
| Q3 25 | $259.7M | $64.3M | ||
| Q2 25 | $253.7M | $70.0M | ||
| Q1 25 | $253.0M | $77.6M | ||
| Q4 24 | $246.6M | $87.5M | ||
| Q3 24 | $243.1M | $95.0M | ||
| Q2 24 | $235.3M | $101.6M |
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.3B | $115.3M | ||
| Q3 25 | $2.3B | $116.3M | ||
| Q2 25 | $2.3B | $122.0M | ||
| Q1 25 | $2.3B | $129.7M | ||
| Q4 24 | $2.2B | $142.8M | ||
| Q3 24 | $2.3B | $143.6M | ||
| Q2 24 | $2.3B | $149.7M |
| Q1 26 | — | — | ||
| Q4 25 | 0.30× | 0.66× | ||
| Q3 25 | 0.31× | 0.66× | ||
| Q2 25 | 0.32× | 0.61× | ||
| Q1 25 | 0.32× | 0.55× | ||
| Q4 24 | 0.33× | 0.46× | ||
| Q3 24 | 0.33× | 0.39× | ||
| Q2 24 | 0.11× | 0.34× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-1.8M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -9.7% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $22.6M | $-1.8M | ||
| Q3 25 | $1.2M | $-8.7M | ||
| Q2 25 | $7.5M | $-7.5M | ||
| Q1 25 | $7.0M | $-11.6M | ||
| Q4 24 | $17.3M | $-3.5M | ||
| Q3 24 | $1.4M | $362.0K | ||
| Q2 24 | $10.2M | $-9.5M |
| Q1 26 | — | — | ||
| Q4 25 | $22.0M | $-2.0M | ||
| Q3 25 | $1.2M | $-8.9M | ||
| Q2 25 | $7.4M | $-7.8M | ||
| Q1 25 | $6.6M | — | ||
| Q4 24 | $16.8M | $-3.6M | ||
| Q3 24 | $1.3M | $311.0K | ||
| Q2 24 | $10.1M | $-9.5M |
| Q1 26 | — | — | ||
| Q4 25 | 134.7% | -9.7% | ||
| Q3 25 | 7.3% | -44.7% | ||
| Q2 25 | 47.8% | -39.6% | ||
| Q1 25 | 45.3% | — | ||
| Q4 24 | 116.9% | -18.9% | ||
| Q3 24 | 9.5% | 1.5% | ||
| Q2 24 | 80.1% | -44.7% |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 0.8% | ||
| Q3 25 | 0.2% | 0.9% | ||
| Q2 25 | 1.0% | 1.1% | ||
| Q1 25 | 2.3% | 0.0% | ||
| Q4 24 | 3.4% | 0.7% | ||
| Q3 24 | 0.8% | 0.3% | ||
| Q2 24 | 0.4% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | 3.82× | — | ||
| Q3 25 | 0.23× | — | ||
| Q2 25 | 1.48× | — | ||
| Q1 25 | 1.45× | — | ||
| Q4 24 | 3.61× | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 2.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JMSB
| Net Interest Income | $16.5M | 98% |
| Noninterest Income | $284.0K | 2% |
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
